In recent years it has purchased the in vivo pharmacology providers RenaSci and Alderley Oncology. /business/mergers-&-acquisitions/Pharma-services-firm-Sygnature-acquires/98/i38 20201002 Concentrates 98 38 /magazine/98/09838.html Pharma services firm Sygnature acquires DMPK specialist XenoGesis contract research, DMPK, England con bus Michael McCoy business mergers-&-acquisitions Sygnature acquires DMPK specialist Chemical & Engineering News Pharma services firm Sygnature acquires DMPK specialist XenoGesis Pharma services firm Sygnature acquires DMPK specialist XenoGesis
by Michael McCoy | October 02, 2020
/analytical-chemistry/diagnostics/Illumina-pay-8-billion-bring/98/i37 20200926 Concentrates 98 37 /magazine/98/09837.html Illumina to pay $8 billion to bring Grail back into fold Diagnostics, cancer, oncology, liquid biopsy con bus Lisa M. Jarvis analytical-chemistry diagnostics pharmaceuticals oncology Illumina to buy back Grail for $8 billion Chemical & Engineering News Illumina to pay $8 billion to bring Grail back into fold Illumina to pay $8 billion to bring Grail back into fold
by Lisa M. Jarvis | September 26, 2020
/pharmaceuticals/oncology/pt-Compra-de-US-21-bilhes/98/i36 20200921 Aquisição expande o grande portfólio oncológico da empresa de biotecnologia para tumores sólidos Concentrates 98 36 /magazine/98/09836.html Compra de US$ 21 bilhões da Immunomedics pela Gilead impulsiona a indústria dos medicamentos conjugados de anticorpos (ADC) oncology, biotechnology, pharmaceuticals, cancer, M&A con bus Lisa M. Jarvis pharmaceuticals oncology The structure of Trodelvy. Trodelvy antibody-drug-conjugate Compra de US$ 21 bilhões da Immunomedics pela Gilead impulsiona a indústria dos medicamentos conjugados de anticorpos (ADC) Chemical & Engineering News Compra de US$ 21 bilhões da Immunomedics pela Gilead impulsiona a indústria dos medicamentos conjugados de anticorpos (ADC) Compra de US$ 21 bilhões da Immunomedics pela Gilead impulsiona a indústria dos medicamentos conjugados de anticorpos (ADC)
by Lisa M. Jarvis | September 21, 2020
/pharmaceuticals/oncology/Synthekine-launches-82-million-pursue/98/i36 20200919 Concentrates 98 36 /magazine/98/09836.html Synthekine launches with $82 million to pursue engineered cytokines IL-2, cytokines con bus Lisa M. Jarvis pharmaceuticals oncology Synthekine launches to engineer cytokines Chemical & Engineering News Synthekine launches with $82 million to pursue engineered cytokines Synthekine launches with $82 million to pursue engineered cytokines
by Lisa M. Jarvis | September 19, 2020
The 26-person company just hired oncology drug discovery expert Tod Smeal to be its chief scientific officer. Hexagon, one of C&EN’s 10 Start-Ups to Watch in 2018, uses a combination of genomics and computational biology to find fungal toxins that might serve as starting points for drugs for cancer and infectious diseases.
by Megha Satyanarayana | September 17, 2020
On a call with investors, Gilead CEO Daniel O’Day called the drug “a pipeline in a product,” thanks to the potential to expand its use to other cancers and to combine it with other oncology drugs. For Gilead, the deal accelerates a years-long plan to become competitive in the oncology drug market. The firm took the first step in 2017 when it paid nearly $12 billion for cell therapy–focused Kite Pharma, a deal that catapulted it into the blood cancer arena. A year later, O’Day, a Roche executive with deep experience in marketing cancer drugs, was brought in to build a broader portfolio of oncology products. In the past two years, the biotech firm has secured 12 oncology deals, O’Day noted on the call. Many of them—notably its recent $4.9 billion acquisition of Forty Seven—expanded Gilead’s pipeline of blood cancer drugs.
by Lisa M. Jarvis | September 15, 2020
/pharmaceuticals/oncology/Merck-KGaA-invests-antibody-drug/98/i35 20200911 Concentrates 98 35 /magazine/98/09835.html Merck KGaA invests in antibody-drug conjugates Antibody-drug conjugates, oncology, outsourcing con bus Michael McCoy pharmaceuticals oncology business investment Merck KGaA says its facility will be designed to handle materials with extremely low human exposure limits.
by Michael McCoy | September 11, 2020
/pharmaceuticals/oncology/AbbVie-licenses-CD47-inhibitorMab/98/i35 20200911 Concentrates 98 35 /magazine/98/09835.html AbbVie licenses CD47 inhibitor from I-Mab Oncology, biotechnology, cancer, pharmaceuticals con bus Lisa M. Jarvis pharmaceuticals oncology business investment AbbVie buys into I-Mab’s cancer drug Chemical & Engineering News AbbVie licenses CD47 inhibitor from I-Mab AbbVie licenses CD47 inhibitor from I-Mab
by Lisa M. Jarvis | September 11, 2020
Such inhibitors—including Forbius’s lead compound, AVID200—are thought to act synergistically with immuno-oncology drugs. The deal does not include Forbius’s assets not related to TGF-β. /pharmaceuticals/oncology/Bristol-Myers-Squibb-buy-biotech/98/i33 20200829 Concentrates 98 33 /magazine/98/09833.html Bristol Myers Squibb to buy biotech firm Forbius Bristol-Myers Squibb, immuno-oncology con bus Michael McCoy pharmaceuticals oncology Bristol Myers to buy biotech firm Forbius Chemical & Engineering News Bristol Myers Squibb to buy biotech firm Forbius Bristol Myers Squibb to buy biotech firm Forbius
by Michael McCoy | August 29, 2020
The Austin, Texas–based firm was founded in 2015 to create immuno-oncology therapies by engineering patients’ T cells with its T-cell antigen coupler (TAC), a multidomain molecule that guides T cells selectively to tumor cells. Triumvira says TAC modification yields better T cells than those created with current engineering approaches, which typically are not effective against solid tumors. /pharmaceuticals/oncology/Triumvira-raises-funds-improved-T/98/i33 20200828 Concentrates 98 33 /magazine/98/09833.html Triumvira raises funds for improved T-cell therapies cell therapy, cancer CAR-T cell therapy con bus Michael McCoy pharmaceuticals oncology Triumvira raises funds for T-cell drugs Chemical & Engineering News Triumvira raises funds for improved T-cell therapies Triumvira raises funds for improved T-cell therapies
by Michael McCoy | August 28, 2020